1. Song Y, Li S, He C. PPARγ Gene polymorphisms, metabolic disorders, and coronary artery disease. Frontiers in Cardiovascular Medicine. 2022;9:808929. doi:10.3389/fcvm.2022.808929.
2. Sakkers TR, Mokry M, Civelek M, et al. Sex differences in the genetic and molecular mechanisms of coronary artery disease. Atherosclerosis. 2023;384:117279. doi:10.1016/j.atherosclerosis.2023.117279.
3. Riveros-Mckay F, Weale ME, Moore R, et al. Integrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction. Circ Genom Precis Med. 2021;14(4):e000085. doi:10.1161/CIRCGEN.120.003304.
4. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. New England Journal of Medicine. 2007;357(5):443-53. doi:10.1056/NEJMoa072366.
5. Wang H, Liu Z, Shao J, et al. Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants. Genes & Diseases. 2020;9(2):370-80. doi:10.1016/j.gendis.2020.11.003.
6. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. doi:10.1056/NEJMoa1707914.
7. Ghaznavi H, Soltanpour MS. Association study between rs2275913 genetic polymorphism and serum levels of IL 17A with risk of coronary artery disease. Molecular biology research communications. 2020;9(1):35-40. doi:10.22099/mbrc.2020.35442.1463.
8. Yao H, Pang Y, Chen Y, et al. Association between interleukin 6 gene polymorphism and severity of coronary artery disease in patients with diabetes. Diabetes, Metabolic Syndrome and Obesity. 2023;16:3599-608. doi:10.2147/DMSO.S427873.
9. Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int. J. Mol. Sci. 2021;22(8):3850. doi:10.3390/ijms22083850.
10. Malinowski D, Bochniak O, Luterek-Puszyńska K, et al. Genetic Risk Factors Related to Coronary Artery Disease and Role of Transforming Growth Factor Beta 1 Polymorphisms. Genes. 2023;14(7):1425. doi:10.3390/genes14071425.
11. Rafaqat S, Azam A, Hafeez R, et al. Role of interleukins in the pathogenesis of coronary heart disease: A literature review. World J Cardiol. 2025;17(3):103947. doi:10.4330/wjc.v17.i3.103947.
12. Grira N, Lahidheb D, Lamine O, et al. The Association of IL 6, TNFα and CRP Gene Polymorphisms with Coronary Artery Disease in a Tunisian Population: A Case-Control study. Biochem Genet. 2021;59(3):751-66. doi:10.1007/s10528-021-10035-0.
13. Fang Y, Xie H, Lin Z. Association between IL 1P +3954C/T polymorphism and myocardial infarction risk. A meta-analysis. Medicine. 2018;97(20):11645. doi:101097/md.0000000000011645.
14. Николаева А.М., Бабушкина Н.П., Рябов В.В. Некоторые про- и противовоспалительные цитокины, полиморфные варианты их генов и постинфарктное ремоделирование сердца. Российский кардиологический журнал. 2020;25(10):4007. doi:10.15829/1560-4071-2020-4007. EDN: LCCDHZ.
15. Yang B, Zhao H, Bin X, et al. Influence of interleukin 1 beta gene polymorphisms on the risk of myocardial infarction and ischemic stroke at young age in vivo and vitro. International Journal of Clinical and Experimental Pathology. 2015;8(11):13806-13. doi:10.1161/01.atv.0000150039.60906.02.
16. Mooney RE, Linden GJ, Winning L, et al. Association of TGFB1 rs1800469 and BCMO1 rs6564851 with coronary heart disease and IL1B rs16944 with all-cause mortality in men from the Northern Ireland PRIME study. PLoS One. 2022;17(8):e0273333. doi:10.1371/journal.pone.0273333.
17. Luo S, Zhang J, Li B, et al. Predictive value of baseline C-reactive protein level in patients with stable coronary artery disease: a meta-analysis. Medicine. 2022;101(35):e30285. doi:10.1097/MD.0000000000030331.
18. Amezcua-Castillo E, González-Pacheco H, Sáenz-San Martín A, et al. C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease-Advancing toward Precision Medicine. Biomedicines. 2023;11(9):2444. doi:10.3390/biomedicines11092444.
19. Богданов Л.А., Кошелев В.А., Мухамадияров Р.А. и др. Современные подходы к идентификации клеточных маркеров дисфункции эндотелия. Комплексные проблемы сердечно-сосудистых заболеваний. 2024;13(3S):191-207. doi:10.17802/2306-1278-2024-13-3S-191-207.
20. Severino P, D’Amato A, Prosperi S, et al. Potential Role of eNOS Genetic Variants in Ischemic Heart Disease Susceptibility and Clinical Presentation. J. Cardiovasc. Dev. Dis. 2021;8(9):116. doi:10.3390/jcdd8090116.
21. Pawlik A, Błaszczyk H, Rać M, et al. NOS3 Gene rs1799983 and rs2070744 Polymorphisms in Patients with Unstable Angina. J Vasc Res. 2020;57(3):136-42. doi:10.1159/000506160.
22. Vargas-Alarcon G, Vallejo M, Posadas-Romero C, et al. The –974C>A (rs3087459) gene polymorphism in the endothelin gene (EDN1) is associated with risk of developing acute coronary syndrome in Mexican patients. Gene. 2014;542(2):258-62. doi:10.1016/j.gene.2013.09.003.
23. Gupta A. An Overview of Gene Variants of Endothelin 1: A Critical Regulator of Endothelial Dysfunction. In: Abukabda A, Fonner C. eds. Endothelial Dysfunction — A Novel Paradigm. 2023. ISBN: 978-1-80356-627-6.
24. Iwanicki T, Iwanicka J, Jarosz A, et al. Association between rs5370 and rs9349379 polymorphisms and coronary artery disease in Polish population. Pomeranian Journal of Life Sciences. 2022;68(4):67-72. doi:10.21164/pomjlifesci.846.
25. Nawaz SK, Yousaf M, Rani A, et al. Endothelin 1 gene variant rs5370 and risk of coronary artery disease in the local population of Pakistan, a case-control study. Pure and Applied Biology (PAB). 2021;10(4):1427-35. doi:10.19045/bspab.2021.100148.
26. Tu G, Fang Z, Zhao Y, et al. Association of +138I/D and Lys198Asn Polymorphisms in the Endothelin 1 Gene with Early Onset of Coronary Artery Disease among the Chinese Han Population. Med Sci Monit. 2020;26:e921542. doi:10.12659/MSM.921542.
27. Lazarenko V, Churilin M, Azarova I, et al. Comprehensive Statistical and Bioinformatics Analysis in the Deciphering of Putative Mechanisms by Which Lipid-Associated GWAS Loci Contribute to Coronary Artery Disease. Biomedicines. 2022;10(2):259. doi:10.3390/biomedicines10020259.
28. Jin JL, Zhang HW, Cao YX, et al. Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovascular diabetology. 2020;19(1):45. doi:10.1186/s12933-020-01015-6.
29. Raman P, Khanal S. Leptin in Atherosclerosis: Focus on Macrophages, Endothelial and Smooth Muscle Cells. Int. J. Mol. Sci. 2021;22(11):5446. doi:10.3390/ijms22115446.
30. Chen MC, Wang JH, Lee CJ, et al. Association between hyperleptinemia and cardiovascular outcomes in patients with coronary artery disease. Ther. Clin. Risk Manag. 2018;14:1855-62. doi:10.2147/TCRM.S172231.
31. Горбатовская Е.Е., Белик Е.В., Дылева Ю.А. и др. Изменение экспрессии изоформ LEPR в локальных жировых депо при коронарном атеросклерозе и приобретенных пороках сердца. Российский кардиологический журнал. 2024;29(8):5826. doi:10.15829/1560-4071-2024-5826. EDN: RUVAOW.
32. Veerabathiran R, P A, Bk I, et al. Genetic predisposition of LEPR (rs1137101) gene polymorphism related to type 2 diabetes mellitus–a meta-analysis. Annals of Medicine. 2023;55(2):2302520. doi:10.1080/07853890.2024.2302520.